** Shares of drug developer Vivani Medical rise 4.2% to $2.24 premarket
** VANI appoints former CEO of Amylin Pharmaceuticals, Daniel Bradbury, to its Board of Directors
** Bradbury headed Amylin Pharmaceuticals until its acquisition by Bristol-Myers Squibb in 2012
** Appointment comes as VANI prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management
** Co last month said that its experimental under-the-skin drug implant helped reduce weight in obese mice in a pre-clinical trial, sending its shares up more than five-fold
** Up to last close, stock has risen 97.2% in the last 12 months
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com;))
Comments